Norstella Executive and Leadership Team

Michael Gallup, the Chief Executive Officer at Norstella, directs the overarching strategic vision for the organization. By integrating diverse entities like Citeline and MMIT, the Chief Executive Officer ensures a unified approach to solving complex pharmaceutical challenges. This leadership role involves driving global expansion and fostering innovation across the entire drug development life cycle. Michael Gallup maintains focus on delivering high-value intelligence solutions that improve patient access worldwide. Through the alignment of advanced machine learning and real-world data assets, the Chief Executive Officer optimizes commercial decision-making for life sciences clients. By cultivating a culture of excellence, Gallup secures the company's position as a premier provider of pharma intelligence. The Chief Executive Officer oversees the executive team to ensure operational synergy, ultimately supporting the mission of transforming how life sciences companies bring critical therapies to market through superior data-driven insights.

Roberto Simon, the Chief Financial Officer at Norstella, manages the fiscal health and capital allocation strategies of the organization. Overseeing financial planning, reporting, and risk management, the Chief Financial Officer ensures that resources support the company's mission of providing critical pharma intelligence. This leadership role involves analyzing market trends to guide investment in advanced technologies like machine learning and real-world data platforms. Roberto Simon maintains strict oversight of budgetary discipline while enabling the scaling of operations across global regions. By collaborating with the executive team, the Chief Financial Officer aligns financial performance with long-term strategic objectives. Simon drives efficiency through robust financial modeling and data-backed insights, ensuring the company remains agile in a competitive landscape. The Chief Financial Officer supports the integration of new acquisitions, facilitating seamless growth and maintaining the financial integrity required to deliver high-quality advisory services to life sciences clients.

Suzanne Caruso, the President, Citeline Clinical, Regulatory & Strategic Intelligence At Norstella, leads the operational and strategic direction of the company's clinical and regulatory intelligence divisions. Overseeing the delivery of comprehensive data solutions, the President, Citeline Clinical, Regulatory & Strategic Intelligence At Norstella ensures that clients receive the critical information needed for pipeline management and regulatory compliance. This leadership role involves managing the integration of clinical trial data and strategic market intelligence to support the entire drug development life cycle. Suzanne Caruso aligns the efforts of these divisions with the company's mission of accelerating patient access. By fostering innovation in how clinical data is analyzed and presented, the President, Citeline Clinical, Regulatory & Strategic Intelligence At Norstella enhances the company's value proposition. Caruso collaborates with other leaders to ensure that the company's intelligence services remain essential for pharmaceutical decision-makers, driving growth and operational excellence across global markets.

Joshua Murphy, the Chief Revenue Officer at Norstella, architects the global commercial strategy to drive sustainable growth. Overseeing the sales and business development functions, the Chief Revenue Officer ensures that life sciences clients receive tailored access to market-leading intelligence solutions. This leadership role involves managing complex client relationships and expanding the company's footprint across international markets. Joshua Murphy aligns revenue targets with the broader organizational goal of improving patient access through data-driven decision-making. By leveraging predictive analytics and expert advisory services, the Chief Revenue Officer maximizes the value delivered to pharmaceutical partners. Murphy coordinates with other C-suite leaders to refine go-to-market strategies, ensuring that the company remains at the forefront of the industry. Through rigorous market analysis and strategic outreach, the Chief Revenue Officer secures long-term financial stability while consistently meeting the evolving needs of the global life sciences sector.

Andy Augustine, the Chief Technology Officer at Norstella, directs the development and implementation of cutting-edge data solutions. Overseeing the engineering and product development teams, the Chief Technology Officer ensures that the company's technological infrastructure supports complex pharmaceutical intelligence needs. This leadership role involves architecting scalable platforms that utilize machine learning and predictive analytics to process vast amounts of scarce data. Andy Augustine maintains a focus on innovation, ensuring that the company's digital tools remain at the forefront of the life sciences industry. By integrating diverse data streams from across the organization, the Chief Technology Officer enables clients to make informed decisions throughout the drug development life cycle. Augustine collaborates with other leaders to align technical capabilities with market demands, driving operational efficiency and product excellence. The Chief Technology Officer secures the company's competitive advantage by continuously evolving the technological framework to meet the sophisticated requirements of global pharmaceutical partners.

Joel Keefe, the Chief Revenue Officer, Mmit, Skipta, Panalgo, Rwd & Evidence Generation at Norstella, drives commercial success within the real-world data and evidence generation segments. Overseeing the revenue streams for these specialized units, the Chief Revenue Officer, Mmit, Skipta, Panalgo, Rwd & Evidence Generation ensures that clients leverage high-quality evidence to support market access strategies. This leadership role involves managing the integration of real-world data assets to provide actionable insights for pharmaceutical decision-makers. Joel Keefe aligns the commercial efforts of these specific business lines with the broader organizational mission of improving patient access. By focusing on the unique needs of the evidence generation market, the Chief Revenue Officer, Mmit, Skipta, Panalgo, Rwd & Evidence Generation expands the company's influence in North American and global markets. Keefe fosters strong partnerships with life sciences firms, ensuring that the company's advanced analytics platforms deliver measurable value and support critical commercial outcomes.

Kevin D'Ambrosia, the Chief Revenue Officer, Panalgoand Mmit Rwd & Skipta at Norstella, manages the strategic growth of the company's specialized digital and community-based intelligence platforms. Overseeing the revenue generation for these specific channels, the Chief Revenue Officer, Panalgoand Mmit Rwd & Skipta ensures that the company effectively reaches key stakeholders in the pharmaceutical ecosystem. This leadership role involves optimizing the delivery of real-world data solutions and professional community engagement tools to drive client adoption. Kevin D'Ambrosia aligns these commercial activities with the company's overarching goal of streamlining drug development processes. By focusing on the unique value propositions of Panalgo and Skipta, the Chief Revenue Officer, Panalgoand Mmit Rwd & Skipta enhances the company's market presence. D'Ambrosia collaborates with cross-functional teams to refine service offerings, ensuring that the company provides comprehensive support for evidence-based decision-making across the global life sciences landscape.

Shrinal Patel, the Chief Medical Officer at Norstella, provides clinical expertise and scientific leadership to guide the company's intelligence solutions. Overseeing the medical integrity of data assets and advisory services, the Chief Medical Officer ensures that all insights are grounded in rigorous clinical standards. This leadership role involves interpreting complex medical data to help life sciences clients navigate the regulatory and clinical hurdles of drug development. Shrinal Patel maintains a focus on patient-centric outcomes, ensuring that the company's tools effectively support the goal of improving access to life-saving therapies. By collaborating with the technology and product teams, the Chief Medical Officer validates the clinical relevance of predictive analytics and real-world evidence. Patel serves as a key advisor to the executive team, providing the medical perspective necessary to maintain the company's reputation for excellence. The Chief Medical Officer drives the scientific strategy, ensuring that the company remains a trusted partner in the global pharmaceutical industry.